The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 8, 1998, Pages 2699-2705

  Diamanti Kandarakis, Evanthia ^a,c   Mitrakou, Asimina ^a   Raptis, Sotos ^a   Tolis, George ^a   Duleba, Antoni J ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANDROGEN; CATECHOLAMINE; CHOLESTEROL; FLUTAMIDE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; NORADRENALIN; TRIACYLGLYCEROL;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DYSLIPIDEMIA; FEMALE; HUMAN; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; OBESITY; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

FALLOPIA;

EID: 0031726522     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.8.5041     Document Type: Article

References (50)

1. Dunaif A, Givens JR, Haseltine F, Merriam GR. 1992 The Polycystic ovary syndrome. Cambridge: Blackwell.
2. Burghen GA, Givens JR, Kitabchi AE. 1980 Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 50:113-116.
3. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. 1983 Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 57:356-359.
4. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. 1987 Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 65:499-507.
5. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. 1985 Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 61:946-951.
6. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. 1992 Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf). 37:119-125.
7. Diamanti-Kandarakis E, Dunaif A. 1996 New perspectives in polycystic ovary syndrome. Trends Endocrinol Metab. 7:267-271.
8. Mahabeer S, Naidoo C, Norman RJ, Jialal I, Reddi K, Joubert SM. 1990 Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Horm Metab Res. 22:537-540.
9. Dahlgren E, Johansson S, Lindsted G, et al. 1992 Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 57:505-513.
10. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. 1992 Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand. 71:599-604.
11. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson Jr SK. 1996 Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol. 174:1224-1229.
12. Wild RA, Applebaum-Bowden D, Demers LM, et al. 1990 Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgens. Clin Chem. 36:283-289.
13. Senoz S, Ozaksit G, Turhan NO, Gulekli B, Gokmen O. 1994 Lipid profiles in women with hirsutism and polycystic ovaries. Gynecol Endocrinol. 8:33-37.
14. Holte J, Bergh T, Berne C, Lithell H. 1994 Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf). 41:463-471.
15. Talbott E, Guzick D, Clerici A, et al. 1995 Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 15:821-826.
16. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. 1977 High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62:707-714.
17. Gordon T, Kannel WB, Castelli WP, Dawber TR. 1981 Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med. 141:1128-1131.
18. Graf MJ, Richards CJ, Brown V, Meissner L, Dunaif A. 1990 The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol (Oxf). 33:119-131.
19. Robinson S, Henderson AD, Gelding SV, et al. 1996 Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 44:277-284.
20. Sorva R, Kuusi T, Dunkel L, Taskinen MR. 1988 Effects of endogenous sex steroids on serum lipoproteins and postheparin plasma lipolytic enzymes. J Clin Endocrinol Metab. 66:4018-413.
21. Yki-Jarvinen H, Taskinen MR, Koivisto VA, Nikkila EA. 1984 Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in man. Diabetologia. 27:364-369.
22. Ek I, Arner P, Bergqvist A, Carlstrom K, Wahrenberg H. 1997 Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance? J Clin Endocrinol Metab. 82:1147-1153.
23. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, et al. 1995 Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism. 44:525-531.
24. Moghetti P, Tosi F, Castello R, et al. 1996 The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab. 81:952-960.
25. Pasquali R, Casimirri F, Balestra V, et al. 1991 The relative contribution of androgens and insulin in determining abdominal body fat distribution in premenopausal women. J Endocr Invest. 14:839-846
26. Pasquali R, Casimirri F, Cantobelli S, et al. 1993 Insulin and androgen relationships with abdominal body fat distribution in women with and without hyperandrogenism. Horm Res. 39:179-187.
27. Seidell JC, Cigolini M, Deurenberg P, Oosterlee A, Doombos G. 1989 Fat distribution, androgens, and metabolism in nonobese women. Am J Clin Nutr. 50:269-273.
28. Lovejoy JC, Bray GA, Bourgeois MO, et al. 1996 Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women-a clinical research center study. J Clin Endocrinol Metab. 81:2198-2203.
29. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. 1986 Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest. 78:1648-1657.
30. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. 1983 Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab. 57:304-310.
31. Holmang A, Svedberg J, Jennische E, Bjorntorp P. 1990 Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 259:E555-E560.
32. Holmang A, Larsson B-M, Brzezinska Z, Bjorntorp P. 1992 Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 262:E851-E855.
33. Rebuffe-Scrive M, Marin P, Bjorntorp P. 1991 Effect of testosterone on abdominal adipose tissue in men. Int J Obesity. 15:791-795.
34. Bhasin S, Swerdloff RS, Steiner B, et al. 1992 A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab. 74:75-83.
35. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, et al. 1996 Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 121:35-43.
36. Kissebah AH, Vydelingum N, Murray R, et al. 1982 Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrionol Metab. 54:254-260.
37. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. 1993 Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 118:860-864.
38. Wallace C, Lalor EA, Chik CL. 1993 Hepatotoxicity complicating flutamide treatment of hirsutism. Ann Intern Med. 119:1150.
39. Diamanti-Kandarakis E, Tolis G, Duleba AJ. 1995 Androgens and therapeutic aspects of antiandrogens in women. J Soc Gynecol Invest. 2:557-592.
40. Fain JN, Garcia-Sainz A. 1983 Adrenergic regulation of adipocyte metabolism. J Lipid Res. 24:945-966.
41. Eri LM, Urdal P. 1995 Effects of the nonsteroidal antiandrogen casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. Eur Urol. 27:274-279.
42. Wallentin L, Varenhorst E. 1980 Plasma lipoproteins during treatment with cyproterone acetate in men with prostatic carcinoma. J Clin Endocrinol Metab. 51:1118-1122.
43. Gillatt DA, Bolton CH, Chadwick D, Downs LG, Hopton MI, Gingell JC. 1993 Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues. Br J Urol. 71:728-730.
44. Balzano S, Cappa M, Migliari R, et al. 1988 The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J Endocrinol Invest. 11:693-696.
45. Nestler JE, Powers LP, Matt DW, et al. 1991 A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocriol Metab. 72:83-89.
46. Friedl KE, Jones RE, Hannan CJ, Plymate SR. 1989 The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab. 68:971-977.
47. Brown TR, Greene FE, Bardin CW. 1976 Androgen receptor dependent and independent activities of testosterone on hepatic microsomal drug metabolism. Endocrinology. 99:1353-1362.
48. Winneker RC, Wagner MM, Shaw CJ, Snyder BW. 1989 Antiandrogens do not reverse androgen-induced inhibition of sex hormone-binding globulin levels in adult female rhesus monkeys. Endocrinology. 125:715-719.
49. Cusan L, Dupont A, Gomez J-L, Tremblay RR, Labrie F. 1994 Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 61:281-287.
50. Pucci E, Genizzani AD, Monzani F, et al. 1995 Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol Endocrinol. 9:221-228.